Host-Directed Therapies for Tuberculosis

TB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entir...

Full description

Saved in:
Bibliographic Details
Other Authors: Venketaraman, Vishwanath (Editor)
Format: Book Chapter
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03112naaaa2200709uu 4500
001 doab_20_500_12854_69310
005 20210501
020 |a books978-3-03943-502-9 
020 |a 9783039435012 
020 |a 9783039435029 
024 7 |a 10.3390/books978-3-03943-502-9  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a GP  |2 bicssc 
072 7 |a PS  |2 bicssc 
100 1 |a Venketaraman, Vishwanath  |4 edt 
700 1 |a Venketaraman, Vishwanath  |4 oth 
245 1 0 |a Host-Directed Therapies for Tuberculosis 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (120 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a TB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
650 7 |a Biology, life sciences  |2 bicssc 
653 |a Mycobacterium tuberculosis 
653 |a host-directed therapies 
653 |a immune responses 
653 |a tuberculosis 
653 |a lung cancer 
653 |a misdiagnosis 
653 |a invasive procedure 
653 |a revising 
653 |a antiplatelet 
653 |a aspirin 
653 |a immunomodulation 
653 |a survival 
653 |a Taiwan 
653 |a latent infection 
653 |a pulmonary 
653 |a rabbit 
653 |a iron supplementation 
653 |a pathology 
653 |a immune response 
653 |a gene expression 
653 |a Perls' stain 
653 |a autophagy 
653 |a M. tb 
653 |a BCG vaccination 
653 |a immune exhaustion 
653 |a glutathione 
653 |a cytokines 
653 |a granulomas 
653 |a type 2 diabetes 
653 |a co-morbidities 
653 |a co-infections 
653 |a inflammation 
653 |a redox imbalance 
653 |a antioxidants 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/3102  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/69310  |7 0  |z DOAB: description of the publication